Hanmi Pharmaceutical   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1973)

Organization Overview

First Clinical Trial
2006
NCT01491204
First Marketed Drug
2013
esomeprazole (nexium)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hanmi pharma. | Hanmi Pharmaceutical co., ltd. | Hanmi Pharmaceutical Co., Ltd. | Hanmi Pharmaceutical Company Limited | Hanmi Pharmaceutical Company Limited ( e-mail: kmpark@hanmi.co.kr ) | Hanmi pharmaceuticals | Hanmi Pharmaceuticals | Hanmi Pharmaceuticals.Co.,Ltd | HANMI PHARMA CO.,Ltd | Hanmi Pharm. Co., Ltd.

Active Ingredients

Marketed Drugs (1)

esomeprazole (nexium) (2013)

Drugs in Phase 4 Trials (17)

acetylcarnitine (1 trial)

acetylsalicylic acid (aspirin) (4 trials)

amlodipine (norvasc) (23 trials)

chlorthalidone (Hygroton) (3 trials)

clopidogrel (plavix) (4 trials)

entecavir (baraclude) (1 trial)

ezetimibe (zetia) (9 trials)

hydrochlorothiazide (esidrix) (1 trial)

losartan (cozaar) (25 trials)

mebhydrolin napadisilate (1 trial)

rosuvastatin (crestor) (15 trials)

simvastatin (zocor) (2 trials)

sorafenib (nexavar) (1 trial)

streptodornase (1 trial)

streptokinase (streptase) (1 trial)

tadalafil (cialis) (5 trials)

urea (1 trial)

Drugs in Phase 3 Trials (34)

atorvastatin (lipitor) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

esomeprazole (nexium) (3 trials)

fluticasone (cutivate) (2 trials)

gefapixant (1 trial)

hcp1202 (1 trial)

hcp2102 (1 trial)

hgp0711 (1 trial)

hgp1201 (4 trials)

hgp1909 (2 trials)

hip0612 (1 trial)

hip1601 (4 trials)

hip2101 (2 trials)

hpp2101 (1 trial)

hpp2102 (1 trial)

hpp2104 (1 trial)

hpp2201 (1 trial)

hpp2202 (1 trial)

irbesartan (avapro) (2 trials)

levocarnitine (carnitor) (1 trial)

levocetirizine (xyzal) (6 trials)

melissa officinalis (1 trial)

montelukast (singulair) (6 trials)

mycophenolate (CellCept) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

pravastatin (pravachol) (5 trials)

prednisone (meticorten) (1 trial)

pseudoephedrine (Benylin) (1 trial)

rld2001 (4 trials)

rld2004 (2 trials)

sildenafil (viagra) (2 trials)

tamsulosin (flomax) (7 trials)

tiotropium (spiriva) (1 trial)

Drugs in Phase 2 Trials (22)

autologous microbiome (1 trial)

bi 1482694 (5 trials)

eperisone (2 trials)

flx475 (1 trial)

hm11260c (6 trials)

hm15136 (3 trials)

hm15211 (3 trials)

hm15912 (2 trials)

hm43239 (1 trial)

hpp2005 (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

kx2-391 (1 trial)

liraglutide (victoza) (2 trials)

mosapride (1 trial)

olmutinib (2 trials)

paclitaxel (taxol) (4 trials)

pembrolizumab (keytruda) (1 trial)

poziotinib (7 trials)

rld2003 (1 trial)

rld2005 (1 trial)

somatropin (protropin) (2 trials)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 1 Trials (52)

ambroxol (1 trial)

bosentan (tracleer) (1 trial)

capecitabine (xeloda) (1 trial)

cobimetinib (cotellic) (1 trial)

dapagliflozin (farxiga) (2 trials)

epoetin (Epogen) (2 trials)

fenofibrate (fenoglide) (2 trials)

Filgrastim (neupogen) (2 trials)

hcp0816 (2 trials)

hcp0911 (1 trial)

hcp0912 (1 trial)

hcp0918 (1 trial)

hcp1007 (2 trials)

hcp1104 (1 trial)

hcp1305 (1 trial)

hcp1401 (1 trial)

hcp1902 (1 trial)

hcp2001 (1 trial)

hcp2202 (2 trials)

hgp0918 (1 trial)

hgp1405 (1 trial)

hgp1501 (1 trial)

hgp1607 (1 trial)

hgp2001 (1 trial)

hifenac (1 trial)

hip1802 (1 trial)

hip2001 (1 trial)

hip2105 (1 trial)

hm12470 (3 trials)

hm30181 (4 trials)

hm95573 (3 trials)

hm97662 (1 trial)

huo-luo-xiao-ling (2 trials)

icosapent ethyl (vascepa) (1 trial)

iloperidone (fanapt) (1 trial)

insulin human (humulin) (3 trials)

levodropropizine (1 trial)

loperamide (imodium) (1 trial)

loteprednol (lotemax) (1 trial)

metformin (glucophage) (2 trials)

oratecan (1 trial)

oseltamivir (tamiflu) (2 trials)

rld2007 (2 trials)

rld2008 (2 trials)

rld2102 (1 trial)

rld2104 (1 trial)

rld2202 (3 trials)

rld2203 (3 trials)

sitagliptin (januvia) (5 trials)

solifenacin (vesicare) (1 trial)

tenofovir (viread) (1 trial)

vildagliptin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Aortic Valve Insufficiency (Phase 4)

Aortic Valve Stenosis (Phase 4)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Asthma (Phase 1)

Back Pain (Phase 2)

Body Weight (Phase 2)

Breast Neoplasms (Phase 2)

Bronchitis (Phase 4)

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cerebrovascular Disorders (Phase 4)

Cognitive Dysfunction (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 2)

Diarrhea (Phase 2)

Dwarfism, Pituitary (Phase 2)

Dyslipidemias (Phase 3)

Endocrine System Diseases (Phase 2)

Erectile Dysfunction (Phase 4)

Essential Hypertension (Phase 3)

Fatty Liver (Phase 2)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Stromal Tumors (Phase 3)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Heart Diseases (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 4)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Hyperplasia (Phase 3)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 3)

Hypertrophy (Phase 4)

Hypertrophy, Left Ventricular (Phase 4)

Infections (Phase 4)

Irritable Bowel Syndrome (Phase 2)

Kidney Diseases (Phase 4)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Low Back Pain (Phase 2)

Lung Diseases, Obstructive (Phase 3)

Lung Neoplasms (Phase 2)

Metabolic Syndrome (Phase 3)

Muscle Cramp (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obesity (Phase 3)

Obesity, Abdominal (Phase 3)

Overweight (Phase 1)

Plaque, Atherosclerotic (Phase 4)

Prostatic Hyperplasia (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Respiratory Tract Infections (Phase 4)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Vasomotor (Phase 3)

Spasm (Phase 3)

Stomach Neoplasms (Phase 2)

Stroke (Phase 4)

Syndrome (Phase 3)

Urinary Bladder, Overactive (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 168
  • # of Trial APIs: 125